Blumberg Institute Distinguished Professor Richard G. Pestell, MD, PhD FACP, FRACP, MBA, gave presentations recently at two international scientific conferences on a promising potential therapy for metastatic triple-negative breast cancer.
The new findings presented at European Society for Medical Oncology meeting in Munich May 15 and an AACR conference in Montreal in September reveal that blocking CCR5 with the monoclonal antibody leronlimab resulted in prolonged survival in patients with metastatic triple-negative breast cancer who had failed at least 2 prior types of treatment.
Patients receiving leronlimab—especially in combination with immune checkpoint inhibitors—remain alive, currently with a ~60-month median survival. Mechanistic studies showed that CCR5 inhibition reawakens anti-tumor immunity by reversing T-cell exhaustion and overcoming ICI resistance.
According to Dr. Pestell, who initiated the study in 2018, and received Fast Track designation for the study in 2019, suggested that “these results warrant further follow up studies. The findings suggesting leronlimab may augment immune therapy for cancer is an important area with the potential to redefine treatment for aggressive, immune-refractory cancers.”
Dr. Pestell is the lead consultant in preclinical and clinical oncology for CytoDyn Inc., the Vancouver, Washington, company that is developing leronlimab. Fast Track is a U.S. Food and Drug Administration program that expedites the development and review of drugs for serious conditions with unmet medical needs.
Blumberg Institute Distinguished Professor Richard G. Pestell, MD, PhD FACP, FRACP, MBA, gave presentations recently at two international scientific conferences on a promising potential therapy for metastatic triple-negative breast cancer.
The new findings presented at European Society for Medical Oncology meeting in Munich May 15 and an AACR conference in Montreal in September reveal that blocking CCR5 with the monoclonal antibody leronlimab resulted in prolonged survival in patients with metastatic triple-negative breast cancer who had failed at least 2 prior types of treatment.
Patients receiving leronlimab—especially in combination with immune checkpoint inhibitors—remain alive, currently with a ~60-month median survival. Mechanistic studies showed that CCR5 inhibition reawakens anti-tumor immunity by reversing T-cell exhaustion and overcoming ICI resistance.
According to Dr. Pestell, who initiated the study in 2018, and received Fast Track designation for the study in 2019, suggested that “these results warrant further follow up studies. The findings suggesting leronlimab may augment immune therapy for cancer is an important area with the potential to redefine treatment for aggressive, immune-refractory cancers.”
Dr. Pestell is the lead consultant in preclinical and clinical oncology for CytoDyn Inc., the Vancouver, Washington, company that is developing leronlimab. Fast Track is a U.S. Food and Drug Administration program that expedites the development and review of drugs for serious conditions with unmet medical needs.